SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-06-171881
Filing Date
2006-08-14
Accepted
2006-08-14 09:42:13
Documents
8
Period of Report
2006-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d10q.htm 10-Q 221060
2 DEVELOPMENT AND COMMERCIALIZATION AGREEMENT dex108.htm EX-10.8 200570
3 EXCLUSIVE LICENSE AGREEMENT dex109.htm EX-10.9 281457
4 FINDER'S AGREEMENT dex1010.htm EX-10.10 19149
5 SECTION 302 CEO CERTIFICATION dex311.htm EX-31.1 8840
6 SECTION 302 CFO CERTIFICATION dex312.htm EX-31.2 8866
7 SECTION 906 CEO CERTIFICATION dex321.htm EX-32.1 3229
8 SECTION 906 CFO CERTIFICATION dex322.htm EX-32.2 3419
  Complete submission text file 0001193125-06-171881.txt   748083
Mailing Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277
Business Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277 704-341-1516
Chelsea Therapeutics International, Ltd. (Filer) CIK: 0001333763 (see all company filings)

IRS No.: 203174202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51462 | Film No.: 061027173
SIC: 2836 Biological Products, (No Diagnostic Substances)